
An experimental pan-coronavirus vaccine developed with AI passed a phase I trial in the UK. Scientists at the University of Cambridge used AI to identify a conserved antigen across coronaviruses including SARS-CoV-2. The vaccine candidate was safe in healthy volunteers and generated an immune response to multiple coronaviruses. Researchers plan to apply the platform to flu and Ebola vaccines.
Tap to vote and see what everyone thinks.
Pfizer And Eli Lilly Partner With Chai Discovery On AI Antibody Models
Summary by ByteBrief